DF 5112
Alternative Names: DF-5112Latest Information Update: 27 May 2026
At a glance
- Originator Dragonfly Therapeutics
- Class Antifibrotics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hidradenitis suppurativa; Primary biliary cirrhosis; Psoriatic arthritis; Rheumatoid arthritis; Systemic scleroderma
Most Recent Events
- 18 May 2026 Early pharmacodynamics data from a phase I trial in Autoimmune disorders released by Dragonfly Therapeutics
- 12 Jan 2026 Phase-I clinical trials in Hidradenitis suppurativa (In volunteers) in Australia (IV) (NCT07232121) (Dragonfly Therapeutics Pipeline, June 2026)
- 12 Jan 2026 Phase-I clinical trials in Hidradenitis suppurativa (In volunteers) in Australia (SC) (NCT07232121) (Dragonfly Therapeutics Pipeline, June 2026)